Related Experiment Video
Updated: Sep 25, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Methotrexate therapy in connective tissue diseases: a review of the literature
Abstract:
Low dose methotrexate (MTX) therapy is now widely used with considerable success in refractory rheumatoid arthritis. Experience with the drug in other connective tissue diseases and vasculitis has been limited. This article reviews hypotheses about the mode of action of MTX, pharmacology and pharmacokinetics, reasons to use cytotoxic agents in the different diseases, and results of MTX therapy. Risk factors, adverse reactions and drug interactions of MTX with other drugs are mentioned. Although based on a small number of patients, data about remarkable clinical improvement in polymyositis, systemic lupus erythematosus and vasculitis suggest that MTX is a potent and effective drug in connective tissue diseases other than rheumatoid arthritis. However, controlled trials are needed to assess the exact value of the drug in these diseases.
Related Concept Videos
Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Therapeutic Drug Monitoring: Affecting Factors

